Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/46036
Title: Identification of dual mTORC1 and mTORC2 inhibitors in melanoma cells: Prodigiosin vs.obatoclax
Author: Espona Fiedler, Margarita
Soto Cerrato, Vanessa
Hosseini, A.
Lizcano, J.M.
Guallar, V.
Quesada, R.
Gao, T.
Pérez Tomás, Ricardo E.
Keywords: Proteïnes quinases
Melanoma
Assaigs clínics
Terapèutica
Protein kinases
Melanoma
Clinical trials
Therapeutics
Issue Date: 15-Feb-2012
Publisher: Elsevier B.V.
Abstract: The PI3K/AKT/mTOR signaling pathway regulates cell proliferation, survival and angiogenesis.The mammalian target of rapamycin (mTOR)is a protein kinase ubiquitously expressed within cells that regulates cell growth and survival by integrating nutrient and hormonal signals. mTOR existsin two complexes, mTORC1 and mTORC2.Hyperactivation of the mTOR protein has been linked to development of cancer, raising mTOR as an attractive target for cancer therapy. Prodigiosin (PG) and obatoclax (OBX), two members of the prodiginines family, are small molecules with anticancer properties which are currently under clinical trials. In the present paper, we demonstrate that mTOR is a molecular target of both prodiginines in melanoma, a highly drug-resistant cancer model. The inhibition of mTORC1 and mTORC2 complexes by PG or OBX resulted in a loss of AKT phosphorylation at S473, preventing its full activation, with no significant effect on T308. The strongest activity inhibition (89%) was induced by PG on mTORC2. Binding assays using Surface Plasmon Resonance (SPR) provide kinetic and affinity data of the interaction of these small molecules with mTOR. In addition, in silico modeling produced a detailed atomic description of the binding modes. These results provide new data to understand the mechanism of action of these molecules, and provide new structural data that will allow the development of more specific mTOR inhibitors for cancer treatment.
Note: Versió postprint del document publicat a: 10.1016/j.bcp.2011.11.027
It is part of: Biochemical Pharmacology, 2012, vol. 83, num. 4, p. 489-496
Related resource: http://dx.doi.org/10.1016/j.bcp.2011.11.027
URI: http://hdl.handle.net/2445/46036
ISSN: 0006-2952
Appears in Collections:Articles publicats en revistes (Patologia i Terapèutica Experimental)

Files in This Item:
File Description SizeFormat 
601832.pdf5.07 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.